Stock Analysis

WemadeLtd Full Year 2024 Earnings: EPS: ₩2,719 (vs ₩5,992 loss in FY 2023)

KOSDAQ:A112040
Source: Shutterstock

WemadeLtd (KOSDAQ:112040) Full Year 2024 Results

Key Financial Results

  • Revenue: ₩712.0b (up 18% from FY 2023).
  • Net income: ₩91.4b (up from ₩200.5b loss in FY 2023).
  • Profit margin: 13% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses.
  • EPS: ₩2,719 (up from ₩5,992 loss in FY 2023).
earnings-and-revenue-growth
KOSDAQ:A112040 Earnings and Revenue Growth February 16th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

WemadeLtd Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Entertainment industry in South Korea.

Performance of the South Korean Entertainment industry.

The company's shares are up 6.2% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on WemadeLtd's balance sheet health.

Valuation is complex, but we're here to simplify it.

Discover if WemadeLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.